Peng Yue
Peng Yue
Director Computational Biology at 23andme Therapeutics
23andme.com üzerinde doğrulanmış e-posta adresine sahip - Ana Sayfa
Başlık
Alıntı yapanlar
Alıntı yapanlar
Yıl
Diverse somatic mutation patterns and pathway alterations in human cancers
Z Kan, BS Jaiswal, J Stinson, V Janakiraman, D Bhatt, HM Stern, P Yue, ...
Nature 466 (7308), 869-873, 2010
9952010
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival
M Schwickart, XD Huang, JR Lill, J Liu, R Ferrando, DM French, ...
Nature 463 (7277), 103-107, 2010
6092010
The mutation spectrum revealed by paired genome sequences from a lung cancer patient
W Lee, Z Jiang, J Liu, PM Haverty, Y Guan, J Stinson, P Yue, Y Zhang, ...
Nature 465 (7297), 473-477, 2010
5722010
SNPs3D: candidate gene and SNP selection for association studies
P Yue, E Melamud, J Moult
BMC bioinformatics 7 (1), 1-15, 2006
5252006
Loss of protein structure stability as a major causative factor in monogenic disease
P Yue, Z Li, J Moult
Journal of molecular biology 353 (2), 459-473, 2005
4052005
Androgen Deprivation Causes Epithelial-Mesenchymal Transition in the Prostate: Implications for Androgen-deprivation Therapy
Y Sun, BE Wang, KG Leong, P Yue, L Li, S Jhunjhunwala, D Chen, K Seo, ...
Cancer Research, 2011
3152011
Somatic mutations in p85α promote tumorigenesis through class IA PI3K activation
BS Jaiswal, V Janakiraman, NM Kljavin, S Chaudhuri, HM Stern, W Wang, ...
Cancer cell 16 (6), 463-474, 2009
2862009
Identification and analysis of deleterious human SNPs
P Yue, J Moult
Journal of molecular biology 356 (5), 1263-1274, 2006
2782006
TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer
S Stinson, MR Lackner, AT Adai, N Yu, HJ Kim, C O’Brien, J Spoerke, ...
Science signaling 4 (177), ra41-ra41, 2011
2662011
The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation
D Raha, TR Wilson, J Peng, D Peterson, P Yue, M Evangelista, C Wilson, ...
Cancer research 74 (13), 3579-3590, 2014
2002014
Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells
D Mérino, SL Khaw, SP Glaser, DJ Anderson, LD Belmont, C Wong, ...
Blood, The Journal of the American Society of Hematology 119 (24), 5807-5816, 2012
1692012
Therapeutic potential of an anti-CD79b antibody–drug conjugate, anti–CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma
D Dornan, F Bennett, Y Chen, M Dennis, D Eaton, K Elkins, D French, ...
Blood 114 (13), 2721-2729, 2009
1672009
Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B
S Menne, DB Tumas, KH Liu, L Thampi, D AlDeghaither, BH Baldwin, ...
Journal of hepatology 62 (6), 1237-1245, 2015
1622015
miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer
S Stinson, MR Lackner, AT Adai, N Yu, HJ Kim, C O’Brien, J Spoerke, ...
Science signaling 4 (186), pt5-pt5, 2011
1452011
miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer
MS Hwang, N Yu, SY Stinson, P Yue, RJ Newman, BB Allan, D Dornan
PloS one 8 (6), e66502, 2013
1382013
Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models
EA Punnoose, JD Leverson, F Peale, ER Boghaert, LD Belmont, N Tan, ...
Molecular cancer therapeutics 15 (5), 1132-1144, 2016
1362016
Navitoclax (ABT-263) reduces Bcl-xL–mediated chemoresistance in ovarian cancer models
M Wong, N Tan, J Zha, FV Peale, P Yue, WJ Fairbrother, LD Belmont
Molecular cancer therapeutics 11 (4), 1026-1035, 2012
872012
Navitoclax enhances the efficacy of taxanes in non–small cell lung cancer models
N Tan, M Malek, J Zha, P Yue, R Kassees, L Berry, WJ Fairbrother, ...
Clinical Cancer Research 17 (6), 1394-1404, 2011
782011
Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models
N Tan, M Wong, MA Nannini, R Hong, LB Lee, S Price, K Williams, ...
Molecular cancer therapeutics 12 (6), 853-864, 2013
692013
Oncogenic activating mutations are associated with local copy gain
B Modrek, L Ge, A Pandita, E Lin, S Mohan, P Yue, S Guerrero, WM Lin, ...
Molecular Cancer Research 7 (8), 1244-1252, 2009
652009
Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.
Makaleler 1–20